Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2013-08-16
- Target Recruit Count
- 140
- Registration Number
- NCT01924624
- Locations
- 🇨🇳
First affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Margarida Magalhaes-Silverman
- Target Recruit Count
- 41
- Registration Number
- NCT01849783
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 4
- Registration Number
- NCT01779167
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT01661400
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT01659658
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01640639
- Locations
- 🇮🇹
University La Sapienza, Rome, Italy
Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01638078
Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT01551641
- Locations
- 🇨🇳
Changzhou No.2 People's Hospital, Changzhou City, Jiangsu, China
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 19
- Registration Number
- NCT01548573
- Locations
- 🇺🇸
University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Velcade (Bortezomib) Consolidation After Transplant
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 256
- Registration Number
- NCT01539083
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.